Clinical Trials Logo

Respiratory Tract Infections clinical trials

View clinical trials related to Respiratory Tract Infections.

Filter by:

NCT ID: NCT05030324 Completed - Influenza Clinical Trials

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

A multicenter, randomized, double-blind, placebo controlled comparative study to evaluate the safety, tolerability and efficacy of XC221 used at 100 mg daily and at 200 mg daily in patients with uncomplicated influenza or other acute viral upper respiratory infections (URIs) for 5 days of treatment. The primary objective of the study is to evaluate the efficacy of ХС221 at 100 mg and at 200 mg in comparison with placebo regarding its effect on the severity and duration of influenza symptoms and symptoms of other viral URIs (fever and other major signs and symptoms). The secondary objective of the study is to evaluate the safety of ХС221 at 100 mg and at 200 mg in comparison with placebo in the treatment of influenza ad other viral URIs.

NCT ID: NCT05028244 Completed - Covid19 Clinical Trials

Evaluation of Serial Ultrasound Screening in ICU COVID-19 Patients

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This clinical trial is designed to evaluate if the periodic screening for deep venous thrombosis by ultrasound of lower extremity in patients with intensive care unit (ICU) patients with COVID 19 impacts on mortality, ICU stay and total length of stay in the hospital, along with other outcomes.

NCT ID: NCT05026801 Withdrawn - Clinical trials for Respiratory Tract Infection Viral

Azithromycin Plus Hydroxychloroquine for COVID-19 Infection

Start date: February 8, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, Phase 3, multi-center trial of the clinical and microbiologic response of patients with a respiratory tract infection (RTI) due to coronavirus treated with a combination of azithromycin and hydroxychloroquine. Approximately 200 patients with symptoms of an RTI who test positive for SARS-CoV-2 by polymerase chain reaction (PCR) will receive a combination of azithromycin 500 mg and hydroxychloroquine 600 mg or matching placebos for six consecutive days. There will be two treatment regimens into which patients are randomized so that all patients will receive some active therapy.

NCT ID: NCT05024890 Completed - Diarrhea Clinical Trials

The Impact of a School-based WASH Intervention on Child Health and School Attendance in Addis Ababa, Ethiopia

WISE
Start date: November 2, 2021
Phase: N/A
Study type: Interventional

This study aims to assess the effects of school-based, comprehensive water, sanitation, and hygiene improvements on child health and educational outcomes in schools in Addis Ababa, Ethiopia. Eligible schools will be randomly allocated to intervention or control groups. Data on pupil absence and illness will be collected longitudinally from students in selected classrooms in each school over the course of one academic year (2021/2022). This study will also assess the effects of the intervention on kindergarten students through parent interviews.

NCT ID: NCT05019456 Recruiting - Influenza Clinical Trials

Exercise and COVID-19 Viral T-cell Immunity

VIC
Start date: March 9, 2021
Phase: N/A
Study type: Interventional

Viruses are a major health problem for the general public and at risk populations. Normally, detection of antibody titers is the gold standard for determining the effectiveness of the immune system following natural or vaccine caused immunization. However, determining the effectiveness of other parts of the immune system are less common due to the difficulties with testing. Furthermore, there is a critical need to address other therapies in case vaccination is not successful in immuncompromised populations. Exercise has been shown to increase the strength of the immune system against many types of viruses and therefore could be simple way to improve immunity against the COVID-19 virus. The aim of this research is to determine the effects of exercise on anti-viral immunity against many types of common viruses before and after vaccination. We hypothesize that exercise will enhance the anti-viral immunity before and after vaccination. Up to 30 healthy volunteers (age 18-44 years) will be recruited to participate in this study. For completion of Aim 1, three visits are needed totaling around 7 hours of the patient's time and for Aim 2, three visits are needed totaling around 4.5 hours of the patient's time. The initial visit will be for pre-screening and if deemed healthy enough to participate, an exercise test to determine the VO2 max of the participant will be conducted. The following visits will require a trained phlebotomist to insert an in-dwelling catheter and participants will undergo a 20-minute incremental exercise trial. Approximately 50mL of blood will be collected at four different timepoints: at rest, 60% VO2 max, 80% VO2 max, and 1-hr post-exercise. All four collected blood samples will be used to expand viral specific T-cells and compare IFN-γ rele

NCT ID: NCT05014516 Terminated - Clinical trials for COVID-19 Respiratory Infection

Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI

LivCovidFree
Start date: August 5, 2021
Phase:
Study type: Observational

In this study the Investigators aim to deploy UTE and HP 129Xe MRI for structural and functional evaluation of persistent lung abnormalities in COVID-19 survivors.

NCT ID: NCT05014048 Completed - Clinical trials for Vitamin D Deficiency

Vitamin D Supplementation for the Prevention of Acute Respiratory Infections: a RCT in Young Finnish Men

Start date: January 4, 2018
Phase: N/A
Study type: Interventional

Vitamin D intervention effects on the prevention of acute respiratory tract infections among Young Finnish Men

NCT ID: NCT05009043 Enrolling by invitation - Covid19 Clinical Trials

COVID-19 Vaccine Hesitancy and Dental Faculty Staff Members in Egypt

Start date: August 15, 2021
Phase:
Study type: Observational

Healthcare workers (HCWs) play a vital role in determining the success of vaccination programs. Patient acceptance and vaccination rely greatly on the utilization and attitude of HCWs towards the vaccine, their attitude also influences patients' adherence to vaccination schedules and their hesitancy. HCWs themselves can be hesitant about a certain vaccine and thus can transfer their negative attitudes to their patients, increasing vaccine hesitancy among the general population. Frontline HCWs are at an increased risk of exposure to COVID-19 due to their direct contact with their patients, working hours, psychological stress and job burnout, they also face stigma. Dental health professionals in particular are at an increased risk due to their occupational hazards that include continuous exposure to body fluids and aerosols, this increases their risk of contracting COVID-19. Therefore vaccinating healthcare workers will be beneficial, not only for themselves, but also for their households and patients.

NCT ID: NCT05007522 Recruiting - Clinical trials for COVID-19 Respiratory Infection

Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19

KICC COVID-19
Start date: May 3, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of ketotifen and indomethacin taken together to improve symptoms related with COVID-19. Ketotifen and indomethacin are medications approved by the Food and Drug Administration (FDA) to treat diseases other than COVID-19. Their use in this study is investigational, meaning they have not been approved by the FDA to treat COVID-19.

NCT ID: NCT05002179 Completed - Clinical trials for Respiratory Tract Infections

Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections

Start date: November 20, 2020
Phase: Phase 4
Study type: Interventional

It is a single-center, randomized, open-label, phase IV study for the explorative investigation of the pharmacological mode-of-action of Echinaforce® extract in the form of Echinaforce® Chewable tablets"- Further, it is aimed to evaluate the effectiveness of the study product for the prevention and treatment of respiratory tract infections in generally healthy adults following a real-life setting. The study covers 2x2 + 1 month of prevention in 120 randomized participants following a tight sampling set-up for sensitive detection of viral infections by RT-qPCR analysis of nasal swabs and seroconversion of SARS-CoV2 IgG/IgM in serum samples.